Apremilast ESTEEM Program Meets Primary and Major Secondary Endpoint...
Celgene International Sarl, a subsidiary of Celgene Corporation , today announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving apremilast 30 mg BID monotherapy in both the ESTEEM 1 & 2 phase III studies.
Join the discussion below, or Read more at PR-inside.com.
Since: Sep 12
#1 Jan 7, 2013
As study found that 10 to 30 percent of psoriasis patient develop psoriatic arthritis, but there may some precautions to avoid these as it causes joint pain, joint stiffness and swelling.
#2 Jan 15, 2013
To learn more about Apremilast, check out http://www.rxwiki.com/apremilast
Add your comments below
|Lower Availability of Omega-3 fatty Acids Assoc...||16 hr||Nataly||1|
|$160B deal to combine Pfizer and Allergan raise...||Thu||Mite Be||21|
|CDC: 'Alarming' increase in STDs||Wed||Belles Echoes||125|
|Pfizer to buy Allergan in $160 billion deal||Nov 25||Cordwainer Trout||6|
|Press release distribution, EDGAR filing, XBRL,...||Nov 23||Buckle Up||1|
|Two murdered at Texas campsite are from Oceanside||Nov 19||James McMillan||1|
|BREAKING NEWS: New details in Katlyn Long inves... (Jun '09)||Nov 18||Roach||158|
Find what you want!
Search Healthcare Industry Forum Now
Copyright © 2015 Topix LLC